

## SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately after the completion of the [REDACTED] and [REDACTED] (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] and the options that have been or may be granted under the Share Option Schemes), the following persons will have an interest or a short position in the Shares or underlying Shares of our Company which will be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any of our subsidiaries:

### Long Position in the Shares

Name of shareholder	Capacity/Nature of Interest	As of the Latest Practicable Date		As of the date of this document		Upon completion of the [REDACTED] Reorganization		Immediately following the completion of the [REDACTED] and the [REDACTED]	
		Number of Shares held/interested	Approximate percentage of shareholding in our Company	Number of Shares held/interested	Approximate percentage of shareholding in our Company	Number of Shares held/interested	Approximate percentage of shareholding in our Company	Number of Shares held/interested	Approximate percentage of shareholding in our Company
GS Cayman <sup>(Notes 1, 3, 4, 5)</sup>	Beneficial Owner	617,500,000	100%	617,500,000	100%	-	-	-	-
GS Corp <sup>(Notes 1, 3, 4 and 5)</sup>	Interest in controlled corporation	617,500,000	100%	617,500,000	100%	-	-	-	-
Dr. Zhang <sup>(Note 1)</sup>	Beneficial Owners	-	-	-	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
	Interest in controlled corporation and interest conferred from proxy <sup>(Note 2)</sup>	617,500,000	100%	617,500,000	100%	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Dr. Wang <sup>(Note 3)</sup>	Interest in controlled corporation	108,625,000	17.59%	108,625,000	17.59%	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Ms. Wu <sup>(Note 4)</sup>	Interest in controlled corporation	108,625,000	17.59%	108,625,000	17.59%	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Ms. Wang <sup>(Note 5)</sup>	Interest in controlled corporation	55,000,000	8.91%	55,000,000	8.91%	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
KPCB China Fund <sup>(Note 6)</sup>	Interest in controlled corporation	111,624,000	18.08%	111,624,000	18.08%	-	-	-	-
KPCB China <sup>(Note 6)</sup>	Beneficial Owner	-	-	-	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
	Interest in controlled corporation	120,000,000	19.43%	120,000,000	19.43%	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

## SUBSTANTIAL SHAREHOLDERS

### Notes:

- (1) Dr. Zhang holds approximately 30.73% of our total issued share capital indirectly through GS Corp (which is owned as to approximately 40.59% by Dr. Zhang, and GS Corp owning approximately 75.71% of GS Cayman and in turn, owning 100% of the issued share capital of our Company) as of the date of this document.
- (2) On May 29, 2015, Ms. Wu signed a proxy agreement whereby she conferred all her voting and related rights in relation to all the shares that she owned in GS Corp to Dr. Zhang, i.e. 108,625,000 shares of GS Corp, representing approximately 17.59% of the issued share capital of our Company as of the date of this document.

All the grantees of the [REDACTED] Option Scheme have also conferred their proxy to Dr. Zhang whereby all their respective voting and relating rights in relation to the options that each grantee holds in our Company, the aggregate of 155,538,420 Shares (immediately before [REDACTED]) or [REDACTED] (immediately before completion of the [REDACTED] and the [REDACTED]), both representing approximately [REDACTED]% of the then respective issued share capital of our Company.

- (3) Dr. Wang holds approximately 23.235% of the issued share capital of GS Corp, which in turn holds approximately 75.71% of the shares in GS Cayman and in turn holds 100% of the issued share capital of our Company as of the date of this document. Immediately after the completion of the [REDACTED] and the [REDACTED] (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] or issued pursuant to the options which have been or may be granted under the Share Option Schemes), Dr. Wang will be interested in [REDACTED] underlying [REDACTED] under the [REDACTED] Options granted. Dr. Wang is the ex-husband of Ms. Wu.
- (4) Ms. Wu holds approximately 23.235% of the issued share capital of GS Corp, which in turn holds approximately 75.71% of the shares in GS Cayman and in turn holds 100% of the issued share capital of our Company as of the date of this document. Ms. Wu is the ex-wife of Dr. Wang.
- (5) Ms. Wang holds approximately 11.76% in the issued share capital of GS Corp, which in turn holds approximately 75.71% of the shares in GS Cayman and in turn holds 100% of the issued share capital of our Company as of the date of this document. Immediately after the completion of the [REDACTED] and the [REDACTED] (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] or issued pursuant to the options which have been or may be granted under the Share Option Schemes), Ms. Wang will be interested in [REDACTED] underlying [REDACTED] under the [REDACTED] Share Options granted.
- (6) KPCB China Fund and KPCB China Founders Fund are exempted limited partnerships established in the Cayman Islands, whose general partner is KPCB China, a company incorporated in the Cayman Islands. KPCB China has sole voting and investment power over the shares in KPCB China Fund and KPCB China Founders Fund. Assuming the Series A-1 Preference Shares held by KPCB China Fund and KPCB China Founders Fund are converted into Shares pursuant to the [REDACTED] Reorganization, KPCB China Fund and KPCB China Founders Fund shall hold [REDACTED] Shares and [REDACTED] Shares, respectively. KPCB China is deemed to be interested in all the Shares held by KPCB China Fund and KPCB China Founders Fund under the SFO.

### Long Position in underlying Shares

Name	Capacity / Nature of Interest	Number of underlying Shares	Approximate percentage in our Company immediately following the completion of the [REDACTED] and the [REDACTED]
Ms. Wang (Note 1)	Beneficial owner	70,075,000	[REDACTED]
Dr. Wang (Note 2)	Beneficial owner	2,000,000	[REDACTED]

## SUBSTANTIAL SHAREHOLDERS

---

---

*Note:*

- (1) Immediately after the completion of the [REDACTED] and the [REDACTED] (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] or issued pursuant to the options which have been or may be granted under the Share Option Schemes), Ms. Wang will be interested in [REDACTED] underlying [REDACTED] under the [REDACTED] Share Options granted.
- (2) Immediately after the completion of the [REDACTED] and the [REDACTED] (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] or issued pursuant to the options which have been or may be granted under the Share Option Schemes), Mr. Wang will be interested in [REDACTED] underlying [REDACTED] under the [REDACTED] Share Options granted.

Save as disclosed herein, our Directors are not aware of any person who will, immediately following completion of the [REDACTED] and the [REDACTED], (without taking into account any Shares which may be issued upon the exercise of the [REDACTED] and the options that have been or may be granted under the Share Option Schemes), have an interest or a short position in any Shares which would be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or be directly or indirectly interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company and are therefore regarded as Substantial Shareholders of our Company.

For persons who will be directly and/or indirectly interested in 10% or more of the nominal value of any class of share capital carrying the rights to vote in all circumstances at the general meeting of our Company immediately following the completion of the [REDACTED] and the [REDACTED], please see the section headed “Statutory and General Information — 7. Further Information about our Directors and Substantial Shareholders — A. Disclosure of Interests” in Appendix V to this document.

Other than as disclosed in this document, the Directors are not aware of any arrangement which may result in a change of control of our Company at a subsequent date.